Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of CEM-102 Compared to Linezolid in Acute Bacterial Skin Infections

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of acute bacterial skin-structure infection (ABSSI) of no more than 7 days duration which was suspected or proven to be caused, at least in part, by a gram-positive pathogen.~* Eligible infections included cellulitis measuring at least 10 cm length and width or 100 cm squared, with or without a focal abscess, and surgical or traumatic wound infections~* Infection which in the opinion of the investigator will require 10-14 days of antibacterial therapy.~* Have at least 3 of the following local and/or systemic symptoms and/or signs of infection: purulent or seropurulent drainage/discharge, erythema, fluctuance, heat/localized warmth, pain/tenderness to palpation, swelling/induration, regional lymph node swelling or tenderness, temperature \>=100.4 degree F, increased white blood cell count, or bandemia.~* Must not have received treatment with another systemic antibiotic for the current ABSSI.~Exclusion Criteria:~* Superficial skin structure infections such as folliculitis, carbuncles, furunculosis, cutaneous abscesses, and simple cellulitis.~* Infections involving burns, human or animal bites, or chronic diabetic foot ulcers.~* Suspected polymicrobial infection involving Pseudomonas aeruginosa~* Anticipated need for \>14 days of antibiotic therapy.~* Infections complicated by the presence of prosthetic materials that will not be removed, such as permanent cardiac pacemaker battery packs, mesh, or joint replacement prosthesis.~* Known significant renal, hepatic, or hematologic impairment.~* Received prior potentially effective antimicrobial therapy for the acute bacterial skin and skin structure infection, unless they were failing therapy after 48 hours or had a gram-positive pathogen non-susceptible to prior therapy identified as a causative pathogen.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Linezolid (Type: ACTIVE_COMPARATOR): 600 mg BID
- CEM-102 Regimen A (Type: EXPERIMENTAL): None
- CEM-102 Regimen B (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).